FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012562754> ?p ?o ?g. }

• W2012562754 endingPage "1994" @default.
• W2012562754 startingPage "1986" @default.
• W2012562754 abstract "We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. A total of59 patients, including 27 with glioblastoma (GBM) and 32 with grade 3 malignant glioma, received 10 mg kg−1 bevacizumab biweekly and 50 mg m−2 etoposide daily for 21 consecutive days each month. The primary end point was a 6-month progression-free survival, and secondary end points included safety and overall survival. Vascular endothelial growth factor (VEGF), VEGFR-2, carbonic anhydrase 9 (CA9) and hypoxia-inducible factor-2α (HIF-2α) were assessed semiquantitatively in archival tumours using immunohistochemistry and were correlated with outcome. Among grade 3 and GBM patients, the 6-month progression-free survivals were 40.6% and 44.4%, the radiographic response rates were 22% and 37% and the median survivals were 63.1 and 44.4 weeks, respectively. Hypertension predicted better outcome among both grade 3 and GBM patients, whereas high CA9 and low VEGF were associated with poorer progression-free survival (PFS) among those with GBM. The most common grade ⩾3 adverse events included neutropaenia (24%), thrombosis (12%), infection (8%) and hypertension (3%). Two patients had asymptomatic, grade 1 intracranial haemorrhage and one on-study death occurred because of pulmonary embolism. Bevacizumab with metronomic etoposide has increased toxicity compared with previous reports of bevacizumab monotherapy. Its anti-tumour activity is similar to that of bevacizumab monotherapy or bevacizumab plus irinotecan. (ClinicalTrials.gov: NCT00612430)." @default.
• W2012562754 created "2016-06-24" @default.
• W2012562754 creator A5002201007 @default.
• W2012562754 creator A5004814459 @default.
• W2012562754 creator A5011590188 @default.
• W2012562754 creator A5014505996 @default.
• W2012562754 creator A5020491326 @default.
• W2012562754 creator A5037596103 @default.
• W2012562754 creator A5043001715 @default.
• W2012562754 creator A5057371623 @default.
• W2012562754 creator A5058264030 @default.
• W2012562754 creator A5059965175 @default.
• W2012562754 creator A5073862375 @default.
• W2012562754 creator A5083472710 @default.
• W2012562754 creator A5085537336 @default.
• W2012562754 date "2009-11-17" @default.
• W2012562754 modified "2023-10-15" @default.
• W2012562754 title "Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study" @default.
• W2012562754 cites W1858161324 @default.
• W2012562754 cites W1929532369 @default.
• W2012562754 cites W1959628099 @default.
• W2012562754 cites W1964752664 @default.
• W2012562754 cites W1964894233 @default.
• W2012562754 cites W1977392502 @default.
• W2012562754 cites W1978041336 @default.
• W2012562754 cites W1984750597 @default.
• W2012562754 cites W1993636025 @default.
• W2012562754 cites W2001355942 @default.
• W2012562754 cites W2002394942 @default.
• W2012562754 cites W2002727873 @default.
• W2012562754 cites W2011680378 @default.
• W2012562754 cites W2013897414 @default.
• W2012562754 cites W2018016372 @default.
• W2012562754 cites W2018929154 @default.
• W2012562754 cites W2020021293 @default.
• W2012562754 cites W2033369193 @default.
• W2012562754 cites W2036044314 @default.
• W2012562754 cites W2040070170 @default.
• W2012562754 cites W2066765068 @default.
• W2012562754 cites W2074823829 @default.
• W2012562754 cites W2093783077 @default.
• W2012562754 cites W2096287682 @default.
• W2012562754 cites W2105431194 @default.
• W2012562754 cites W2116665727 @default.
• W2012562754 cites W2122074158 @default.
• W2012562754 cites W2123421036 @default.
• W2012562754 cites W2127745545 @default.
• W2012562754 cites W2131705241 @default.
• W2012562754 cites W2132697290 @default.
• W2012562754 cites W2133708161 @default.
• W2012562754 cites W2137582962 @default.
• W2012562754 cites W2137832651 @default.
• W2012562754 cites W2140201170 @default.
• W2012562754 cites W2142312148 @default.
• W2012562754 cites W2147535764 @default.
• W2012562754 cites W2148519586 @default.
• W2012562754 cites W2150216446 @default.
• W2012562754 cites W2156928957 @default.
• W2012562754 cites W2161637607 @default.
• W2012562754 cites W2169965478 @default.
• W2012562754 cites W2170367762 @default.
• W2012562754 doi "https://doi.org/10.1038/sj.bjc.6605412" @default.
• W2012562754 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2795427" @default.
• W2012562754 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19920819" @default.
• W2012562754 hasPublicationYear "2009" @default.
• W2012562754 type Work @default.
• W2012562754 sameAs 2012562754 @default.
• W2012562754 citedByCount "190" @default.
• W2012562754 countsByYear W20125627542012 @default.
• W2012562754 countsByYear W20125627542013 @default.
• W2012562754 countsByYear W20125627542014 @default.
• W2012562754 countsByYear W20125627542015 @default.
• W2012562754 countsByYear W20125627542016 @default.
• W2012562754 countsByYear W20125627542017 @default.
• W2012562754 countsByYear W20125627542018 @default.
• W2012562754 countsByYear W20125627542019 @default.
• W2012562754 countsByYear W20125627542020 @default.
• W2012562754 countsByYear W20125627542021 @default.
• W2012562754 countsByYear W20125627542022 @default.
• W2012562754 countsByYear W20125627542023 @default.
• W2012562754 crossrefType "journal-article" @default.
• W2012562754 hasAuthorship W2012562754A5002201007 @default.
• W2012562754 hasAuthorship W2012562754A5004814459 @default.
• W2012562754 hasAuthorship W2012562754A5011590188 @default.
• W2012562754 hasAuthorship W2012562754A5014505996 @default.
• W2012562754 hasAuthorship W2012562754A5020491326 @default.
• W2012562754 hasAuthorship W2012562754A5037596103 @default.
• W2012562754 hasAuthorship W2012562754A5043001715 @default.
• W2012562754 hasAuthorship W2012562754A5057371623 @default.
• W2012562754 hasAuthorship W2012562754A5058264030 @default.
• W2012562754 hasAuthorship W2012562754A5059965175 @default.
• W2012562754 hasAuthorship W2012562754A5073862375 @default.
• W2012562754 hasAuthorship W2012562754A5083472710 @default.
• W2012562754 hasAuthorship W2012562754A5085537336 @default.
• W2012562754 hasBestOaLocation W20125627541 @default.
• W2012562754 hasConcept C126322002 @default.
• W2012562754 hasConcept C141071460 @default.
• W2012562754 hasConcept C143998085 @default.

• next